Audited Financial Results for the 4th Quarter and Financial Year ended 31.03.2026.
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.9 pts less than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vimta Labs reported total income of ₹4,162.79 million for FY2026, up 19.5% from ₹3,482.22 million in FY2025. Revenue from operations grew 18.4% to ₹4,072.90 million. The company posted profit before tax of ₹1,039.53 million (up 15% YoY) and total comprehensive income of ₹775.12 million (up 15.1%). Diluted EPS from continuing operations improved to ₹17.40 from ₹14.93. The board recommended a dividend of ₹2 per share (face value ₹2 each) for FY2025-26, payable to shareholders on record date June 18, 2026. The auditors issued an unmodified opinion. An exceptional item of ₹16.16 million was recorded due to the new labour code impact on gratuity. The company also approved setting up a wholly owned subsidiary in the USA and reappointed Dr. S.P. Vasireddi as Executive Chairman for 5 years.
Strong revenue and profit growth in FY2026, with PAT rising over 50% — this is positive for shareholders. The clean audit opinion and dividend announcement are supportive signals, though EBITDA margin compressed slightly from the prior year.